Bicara Therapeutics Inc [BCAX] stock prices are up 7.03% to $9.90 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCAX shares have gain 6.80% over the last week, with a monthly amount drifted -32.70%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicara Therapeutics Inc [NASDAQ: BCAX] stock has seen the most recent analyst activity on May 23, 2025, when Wells Fargo upgraded its rating to a Equal Weight but kept the price target unchanged to $8 for it. Previously, Wells Fargo started tracking the stock with Underweight rating on April 17, 2025, and set its price target to $8. On February 06, 2025, Wedbush initiated with a Outperform rating and assigned a price target of $31 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $42 on December 06, 2024. Rodman & Renshaw initiated its recommendation with a Buy and recommended $48 as its price target on November 05, 2024. In a note dated October 08, 2024, Stifel initiated an Buy rating and provided a target price of $47 on this stock.
The stock price of Bicara Therapeutics Inc [BCAX] has been fluctuating between $7.80 and $28.09 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Bicara Therapeutics Inc [NASDAQ: BCAX] shares were valued at $9.90 at the most recent close of the market. An investor can expect a potential return of 182.83% based on the average BCAX price forecast.
Analyzing the BCAX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.28 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.36 points at the first support level, and at 8.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.38, and for the 2nd resistance point, it is at 10.86.
Ratios To Look Out For
It’s worth pointing out that Bicara Therapeutics Inc [NASDAQ:BCAX]’s Current Ratio is 24.62. As well, the Quick Ratio is 24.62, while the Cash Ratio is 24.17.
Transactions by insiders
Recent insider trading involved Meisner Lara, Chief Legal Officer, that happened on Mar 14 ’25 when 79146.0 shares were sold. Officer, LARA S. MEISNER completed a deal on Mar 14 ’25 to buy 79146.0 shares. Meanwhile, Director RA CAPITAL MANAGEMENT, L.P. bought 1.83 million shares on Sep 16 ’24.
